| 產(chǎn)品名稱 | MC-TGS17-51 [MC17-51, Mutatect] |
|---|---|
| 商品貨號(hào) | B238046 |
| Organism | Mus musculus, mouse |
| Product Format | frozen |
| Morphology | fibroblast |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | fibrosarcoma |
| Gender | male |
| Strain | C57BL/10 |
| Applications | tumor model |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | The Mutatect mouse tumor model is a series of cell lines (eight are available from ATCC) derived from a murine fibrosarcoma that can grow in culture as well as form subcutaneous tumors in syngeneic C57BL/6 mice. The MC1A fibrosarcoma was induced by methylcholanthrene injection into a C57BL/10 mouse. The resulting tumor was adapted to in vitro growth and a variant named MC1A-C1 was isolated that was capable of growth both in culture and as subcutaneous tumor in 8 to 9 week old female C57BL/6 mice [PubMed 106311342; PubMed: 7577474]. MC1A-C1 cells were treated with N-methyl-N-nitrosourea (MNU) and selected with low concentrations of 6-thioguanine. 6-thioguanine (6-TG) resistant (HPRT-) clones were isolated and screened for tumorigenicity; clone MC-TRG17 was selected. A spontaneously arising 6-thioguanine sensitive, Hypoxanthine - Aminopterin - Thymidine (HAT) resistant revertant named MC-TGS17-51 (ATCC CRL-2799) was identified by selection in HAT. The cells are hypoxanthine phosphoribosyl transferase positive (HPRT+) [PubMed 106311342; PubMed: 7577474]. The Mutatect cell lines can be used in vitro/in vivo for the detection of deletion mutations of the hypoxanthine phosphoribosyl transferase (HPRT) gene. They are also useful for the study of inflammatory infiltration of solid tumors. |
| Clinical Data | The resulting tumor was adapted to in vitro growth and a variant named MC1A-C1 was isolated that was capable of growth both in culture and as subcutaneous tumor in 8 to 9 week old female C57BL/6 mice [PubMed 106311342; PubMed: 7577474]. male |
| Tumorigenic | Yes |
| Effects | Yes, forms subcutaneous tumors in syngeneic C57BL/6 mice. |
| Comments | The Mutatect mouse tumor model is a series of cell lines (eight are available from ATCC) derived from a murine fibrosarcoma that can grow in culture as well as form subcutaneous tumors in syngeneic C57BL/6 mice. The MC1A fibrosarcoma was induced by methylcholanthrene injection into a C57BL/10 mouse. The resulting tumor was adapted to in vitro growth and a variant named MC1A-C1 was isolated that was capable of growth both in culture and as subcutaneous tumor in 8 to 9 week old female C57BL/6 mice [PubMed 106311342; PubMed: 7577474]. MC1A-C1 cells were treated with N-methyl-N-nitrosourea (MNU) and selected with low concentrations of 6-thioguanine. 6-thioguanine (6-TG) resistant (HPRT-) clones were isolated and screened for tumorigenicity; clone MC-TRG17 was selected. A spontaneously arising 6-thioguanine sensitive, Hypoxanthine - Aminopterin - Thymidine (HAT) resistant revertant named MC-TGS17-51 (ATCC CRL-2799) was identified by selection in HAT. The cells are hypoxanthine phosphoribosyl transferase positive (HPRT+) [PubMed 106311342; PubMed: 7577474]. The Mutatect cell lines can be used in vitro/in vivo for the detection of deletion mutations of the hypoxanthine phosphoribosyl transferase (HPRT) gene. They are also useful for the study of inflammatory infiltration of solid tumors. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing | Protocol:
Interval: Maintain cultures at a cell concentration between 1 X 10(4) and 2 X 10(5) cells/cm2 Subcultivation Ratio: A subcultivation of 1:4 to 1:8 is recommended Medium Renewal: Two to three times weekly |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Population Doubling Time | 24 hours |
| Name of Depositor | HC Birnboim |
| References | Birnboim HC, et al. Mutatect: a mouse tumour model for detecting radiation-induced mutations in vivo. Mutat. Res. 430: 275-280, 1999. PubMed: 10631342 Sandhu JK, et al. Effect of dietary vitamin E on spontaneous or nitric oxide donor-induced mutations in a mouse tumor model. J. Natl. Cancer Inst. 92: 1429-1433, 2000. PubMed: 10974079 Haqqani AS, et al. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia Haqqani AS, et al. Constitutive expression of interleukin-8 by Mutatect cells markedly affects their tumor biology. Carcinogenesis 22: 243-250, 2001. PubMed: 11181444 Wilkinson D, et al. Hprt mutants in a transplantable murine tumour arise more frequently in vivo than in vitro. Br. J. Cancer 72: 1234-1240, 1995. PubMed: 7577474 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購買須知 | 查看詳情 |
| 5 | 訂購流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
